Senior executives and investors in the life sciences sector will convene in London on 5-6 February 2019 for the LSX World Congress. The event will feature a variety of keynote discussions, panel debates, and fireside chats designed to examine the strategic challenges facing companies and to give voice to the trends shaping the future of the industry.
The jam-packed agenda brings together speakers with expertise across specialist areas and from all parts of the life sciences development chain. This ranges from sessions on overcoming translational research bottlenecks to building international companies, and from genomics and blockchain applications to longevity.
The two-day congress comprises two conference streams with a focus on biotech, medtech and digital health. In the biotech stream, Forbion’s Sander Slootweg, SR One’s Deborah Harland, Abingworth’s Tim Haines, Eli Lilly’s Johnston Erwin, TVM Capital Life Science’s Hubert Birner and Sofinnova’s Graziano Seghezzi will explore global investment trends and funding models. Later panels will shine a spotlight on financing from seed stage to public markets, featuring firms such Novo Seeds, Bioseed Capital, Deepbridge Capital, High-Tech Gründerfonds, BioGeneration Ventures, Truffle Capital, LSP, Polar Capital, Swedbank Robur, and HBM Partners. Attendees can also gain insight into pharma companies’ views on partnering and M&A in 2019, as well as their evolving role in early-stage collaborations, with speakers from AstraZeneca, Novartis, Boehringer Ingelheim, Roche, MSD, Novo Nordisk, Eli Lilly, and Johnson & Johnson.
Commercial leaders in the medtech stream, including Medtronic’s Chris Cleary, LivaNova’s Matthew Dodds, and Boston Scientific’s Pierre Chauvineau, will consider what is in store for medtech M&A and consolidation over the year ahead, while Panakès Partners, Andera Partners, Asabys Partners, Seroba Life Sciences, and SHS will offer their perspectives on the current state of the investment ecosystem. Delegates can also hear from panels tackling topics such as emerging investment sources, the impact of non-traditional entrants on the industry, what it takes to establish and scale a sustainable medtech business, and how companies are embedding intelligence into medtech and medical devices.
Both streams will incorporate a number of fireside chat-style interviews, where speakers will share lessons they have learnt and their visions for the future. Fireside chats will be conducted with: Alexander Belcredi, CEO at PhagoMed; Yochi Slonim, CEO at Anima Biotech; Thomas Holm Pedersen, CEO at NMD Pharma; Jackie Hunter, Chief Executive at BenevolentBio; Lord Drayson, CEO at Sensyne Health; Carole Longson, former Director at the National Institute for Health and Care Excellence (NICE) and CSO at the Association of the British Pharmaceutical Industry (ABPI); Martin Frost, CEO at CMR Surgical.
In addition to the conference agenda, the LSX World Congress will feature an innovation zone, company showcases, a series of workshops, boot camps and forums, as well as networking and partnering opportunities.
Feature image © Alex – stock.adobe.com